Therapeutic sequencing in inflammatory bowel disease: Determining the optimal position of vedolizumab for long-term Crohn's disease control using real-world evidence.
[en] BACKGROUND: Several biologics are available for the treatment of moderate to severe Crohn's disease, but data to optimize their use are scarce. Vedolizumab (VDZ) is a gut-selective anti-lymphocyte trafficking monoclonal antibody that was approved in 2014 for the treatment of moderate to severe Crohn's disease. Based on real-world evidence, a model was developed to examine the effect of VDZ's position in the treatment sequence on clinical outcomes. OBJECTIVE: The aim of this study was to develop a model using real-world data to investigate how the positioning of VDZ in a sequence of biologic therapies for CD affects clinical effectiveness outcomes of quality-adjusted life-years (QALYS), patient-reported disease activity, and surgery rates. METHODS: A semi-Markov sequential model was developed to identify the optimal position of VDZ in a treatment sequence that included corticosteroids (CS), two biologics, and best supportive care (BSC). Using real-world data, three sequences were compared: VDZ as first (position), second, and last biologic (with anti-tumor necrosis factor alpha agents adalimumab (ADA) and infliximab (IFX) and the anti-interleukin-12 and -23 agent ustekinumab (UST) as alternative biologic treatments). Published real-world evidence informed model inputs. Vedolizumab sequences were compared and ranked based on QALYS, patient-reported outcomes from Crohn's disease activity index scores, or proportion of patients undergoing surgery by the 10-year time horizon for model simulation. Sensitivity analyses were used to evaluate the impact of model input uncertainty. RESULTS: Vedolizumab as the first biologic was the optimal position for this treatment according to all criteria, including yielding the highest QALYs (5.09) versus VDZ in second (4.97) and third (4.96) biologic sequence positions in sequences containing CS, anti-TNFα (aggregated data), UST, and BSC; 1780/2000 (89%) probabilistic simulations. In sequences containing ADA, VDZ, and UST biologics, ADA and VDZ in the first-line biologic position yielded QALYs of 5.09 versus 5.07, respectively. Adalimumab as the first biologic was best for clinical remission. CONCLUSIONS: This simulation model using real-world evidence indicates that positioning VDZ or ADA as the first biologic is likely to lead to improved long-term patient outcomes when compared to administering these treatments later or starting with IFX monotherapy.
Disciplines :
Gastroenterology & hepatology
Author, co-author :
Louis, Edouard ; Université de Liège - ULiège > Département des sciences cliniques > Hépato-gastroentérologie
Litkiewicz, Michal; Modeling and Simulation, Evidera (a part of Thermo Fisher Scientific), London, UK.
Agboton, Christian ; Takeda, Cambridge, Massachusetts, USA.
Armuzzi, Alessandro; IBD Center, IRCCS Humanitas Research Hospital, Rozzano, Milan, Italy. ; Department of Biomedical Sciences, Humanitas University, Pieve Emanuele, Milan, Italy.
Language :
English
Title :
Therapeutic sequencing in inflammatory bowel disease: Determining the optimal position of vedolizumab for long-term Crohn's disease control using real-world evidence.
Danese S, Fiorino G, Peyrin-Biroulet L. Early intervention in Crohn's disease: towards disease modification trials. Gut. 2017;66(12):2179–2187. https://doi.org/10.1136/gutjnl-2017-314519
Chateau T, Peyrin-Biroulet L. Evolving therapeutic goals in Crohn's disease management. Unit Eur Gastro J. 2020;8(2):133–139. https://doi.org/10.1177/2050640619887316
Danese S, Fiorino G, Fernandes C, Peyrin-Biroulet L. Catching the therapeutic window of opportunity in early Crohn's disease. Curr Drug Targets. 2014;15(11):1056–1063. https://doi.org/10.2174/1389450115666140908125738
Turner D, Ricciuto A, Lewis A, D'Amico F, Dhaliwal J, Griffiths AM, et al. STRIDE-II: an update on the selecting therapeutic targets in inflammatory bowel disease (STRIDE) initiative of the international organization for the study of IBD (IOIBD): determining therapeutic goals for treat-to-target strategies in IBD. Gastroenterology. 2021;160(5):1570–1583. https://doi.org/10.1053/j.gastro.2020.12.031
Feuerstein JD, Ho EY, Shmidt E, Singh H, Falck-Ytter Y, Sultan S, et al. AGA clinical practice guidelines on the medical management of moderate to severe luminal and perianal fistulizing Crohn's disease. Gastroenterology. 2021;160(7):2496–2508. https://doi.org/10.1053/j.gastro.2021.04.022
Hamdeh S, Aziz M, Altayar O, Olyaee M, Murad MH, Hanauer SB. Early vs late use of anti-TNFa therapy in adult patients with Crohn disease: a systematic review and meta-analysis. Inflamm Bowel Dis. 2020;26(12):1808–1818. https://doi.org/10.1093/ibd/izaa031
Ungaro RC, Aggarwal S, Topaloglu O, Lee WJ, Clark R, Colombel JF. Systematic review and meta-analysis: efficacy and safety of early biologic treatment in adult and paediatric patients with Crohn's disease. Aliment Pharmacol Ther. 2020;51(9):831–842. https://doi.org/10.1111/apt.15685
George LA, Cross RK. How do we sequence biologic therapies in 2019? Inflamm Bowel Dis. 2020;26(4):617–618.
Roda G, Jharap B, Neeraj N, Colombel JF. Loss of response to anti-TNFs: definition, epidemiology, and management. Clin Transl Gastroenterol. 2016;7(1):e135. https://doi.org/10.1038/ctg.2015.63
Gils A, Dreesen E, Compernolle G, Peeters M, Brouwers E, Tops S, et al. Sa1878 Recent anti-TNF exposure predicts lower vedolizumab trough concentrations in patients with Crohn disease. Gastroenterology. 2017;152(5 Suppl 1):S-380. https://doi.org/10.1016/s0016-5085(17)31513-5
Bressler B, Yarur A, Silverberg MS, Bassel M, Bellaguarda E, Fourment C, et al. Vedolizumab and anti-tumour necrosis factor alpha real-world outcomes in biologic-naive inflammatory bowel disease patients: results from the EVOLVE study. J Crohns Colitis. 2021;15(10):1694–1706. https://doi.org/10.1093/ecco-jcc/jjab058
Ritter TE, Fourment C, Okoro TC, Hardin TC, Van Anglen LJ. 681 Failure of vedolizumab as first-line biologic does not decrease response rates of second-line therapy. Am J Gastroenterol. 2018;113(Suppl):S382–S833. https://doi.org/10.14309/00000434-201810001-00681
Singh S, Fumery M, Sandborn WJ, Murad MH. Systematic review and network meta-analysis: first- and second-line biologic therapies for moderate-severe Crohn's disease. Aliment Pharmacol Ther. 2018;48(4):394–409. https://doi.org/10.1111/apt.14852
Privitera G, Pugliese D, Lopetuso LR, Scaldaferri F, Neri M, Guidi L, et al. Novel trends with biologics in inflammatory bowel disease: sequential and combined approaches. Therap Adv Gastroenterol. 2021;14:17562848211006669. https://doi.org/10.1177/17562848211006669
Scott FI, Shah Y, Lasch K, Luo M, Lewis JD. Assessing the optimal position for vedolizumab in the treatment of ulcerative colitis: a simulation model. Inflamm Bowel Dis. 2018;24(2):286–295. https://doi.org/10.1093/ibd/izx045
Scott FI, Hans AK, Gerich ME, Fennimore B, Mamtani R, Vajravelu RK, et al. Identification of the most effective position for ustekinumab in treatment algorithms for Crohn's disease. Clin Gastroenterol Hepatol. 2021;19(10):2082–2092.e10. https://doi.org/10.1016/j.cgh.2020.08.021
Khanna R, Zou G, D'Haens G, Feagan BG, Sandborn WJ, Vandervoort MK, et al. A retrospective analysis: the development of patient reported outcome measures for the assessment of Crohn's disease activity. Aliment Pharmacol Ther. 2015;41(1):77–86. https://doi.org/10.1111/apt.13001
Peyrin-Biroulet L, Sandborn W, Sands BE, Reinisch W, Bemelman W, Bryant RV, et al. Selecting therapeutic targets in inflammatory bowel disease (STRIDE): determining therapeutic goals for treat-to-target. Am J Gastroenterol. 2015;110(9):1324–1338. https://doi.org/10.1038/ajg.2015.233
R Core Team. R: a language and environment for statistical computing; 2023. https://www.R-project.org/
Wickham H. ggplot2: elegant graphics for data analysis. New York: Springer-Verlag; 2016. ISBN 978-3-319-24277-4.
Ben-Horin S, Novack L, Mao R, Guo J, Zhao Y, Sergienko R, et al. Efficacy of biologic drugs in short-duration versus long-duration inflammatory bowel disease: a systematic review and an individual-patient data meta-analysis of randomized controlled trials. Gastroenterology. 2022;162(2):482–494. https://doi.org/10.1053/j.gastro.2021.10.037
Lenti MV, Dolby V, Clark T, Hall V, Tattersall S, Fairhurst F, et al. A propensity score-matched, real-world comparison of ustekinumab vs vedolizumab as a second-line treatment for Crohn's disease. The Cross Pennine study II. Aliment Pharmacol Ther. 2022;55(7):856–866. https://doi.org/10.1111/apt.16742
Townsend T, Razanskaite V, Michail S, Morgan J, Davies M, Storey D, et al. Comparative effectiveness of vedolizumab and ustekinumab as induction therapy in anti-TNF refractory Crohn’s disease: a multi-centre retrospective cohort study. J Crohns Colitis. 2019;13(Suppl 1):S407–S408. https://doi.org/10.1093/ecco-jcc/jjy222.710
Ylisaukko-Oja T, Aaltonen J, Nuutinen H, Blomster T, Jussila A, Pajala M, et al. High treatment persistence rate and significant endoscopic healing among real-life patients treated with vedolizumab - a Finnish Nationwide Inflammatory Bowel Disease Cohort Study (FINVEDO). Scand J Gastroenterol. 2018;53(2):158–167. https://doi.org/10.1080/00365521.2017.1416160
Ha C, Ullman TA, Siegel CA, Kornbluth A. Patients enrolled in randomized controlled trials do not represent the inflammatory bowel disease patient population. Clin Gastroenterol Hepatol. 2012;10(9):1002–1007. quiz e78. https://doi.org/10.1016/j.cgh.2012.02.004
Sandborn WJ, Feagan BG, Rutgeerts P, Hanauer S, Colombel JF, Sands BE, et al. Vedolizumab as induction and maintenance therapy for Crohn's disease. N Engl J Med. 2013;369(8):711–721. https://doi.org/10.1056/nejmoa1215739
Loftus EV, Sandborn WJ, Wolf DC, Danese S, Chen J, Yao X, et al. Tu1713 Efficacy and safety of 2 or 3 vedolizumab intravenous infusions as induction therapy for ulcerative colitis and Crohn’s disease: results from Visible 1 and 2. Gastroenterology. 2019;156(6 Suppl 1):S-1095. https://doi.org/10.1016/s0016-5085(19)39699-4
Peyrin-Biroulet L, Harmsen WS, Tremaine WJ, Zinsmeister AR, Sandborn WJ, Loftus EV, Jr. Surgery in a population-based cohort of Crohn's disease from Olmsted County, Minnesota (1970-2004). Am J Gastroenterol. 2012;107(11):1693–1701. https://doi.org/10.1038/ajg.2012.298
Ehrenberg R, Griffith J, Theigs C, McDonald B. Dose escalation assessment among targeted immunomodulators in the management of inflammatory bowel disease. J Manag Care Spec Pharm. 2020;26(6):758–765. https://doi.org/10.18553/jmcp.2020.19388
Macaluso FS, Grova M, Saladino M, Cappello M, Demarzo MG, Privitera AC, et al. The effectiveness of ustekinumab and vedolizumab as third-line biologic therapy in patients with Crohn's disease. Dig Liver Dis. 2023;55(4):471–477. https://doi.org/10.1016/j.dld.2022.08.028
Onali S, Pugliese D, Caprioli FA, Orlando A, Biancone L, Nardone OM, et al. An objective comparison of vedolizumab and ustekinumab effectiveness in Crohn's disease patients' failure to TNF-alpha inhibitors. Am J Gastroenterol. 2022;117(8):1279–1287. https://doi.org/10.14309/ajg.0000000000001773
Rayer C, Nachury M, Bourreille A, Roblin X, Peyrin-Biroulet L, Viennot S, et al. Efficacy of ustekinumab, vedolizumab, or a second anti-TNF agent after the failure of a first anti-TNF agent in patients with Crohn's disease: a multicentre retrospective study. BMC Gastroenterol. 2022;22(1):498. https://doi.org/10.1186/s12876-022-02583-5
